Urgent.News

600+ sources. One page. See who else covered it.

Editions

Health & Medicine

Chipotle removes jalapeños amid US salmonella outbreak investigation

Restaurant chain pulls peppers ‘out of an abundance of caution’ as salmonella outbreak sickens 110 people Chipotle said on Tuesday it had removed jalapeños from some of the chain’s restaurants after identifying the peppers as a potential ingredient tied to a salmonella outbreak, replacing them with supplies from different growers. The company said it began tracing ingredients through its supply…

Chipotle removes jalapeños amid US salmonella outbreak investigation

Chipotle has removed jalapeños from some of its restaurants amid an investigation into a salmonella outbreak. The outbreak has sickened 110 people, according to the Minnesota Department of Health.

The company said it identified jalapeños from a common lot as a potential source of the outbreak and replaced them with supplies from different growers. This was done "out of an abundance of caution," Chipotle said.

The Minnesota Department of Health reported that nearly 90% of those interviewed, 84 patients, reported eating at Chipotle from mid-June to July. CBS News reported that Chipotle pulled the peppers and replaced them with product from another grower amid the food-poisoning probe.

Brief written by urgent.news from Guardian Health, CBS News, Forbes — 3 reports on this story. Machine-written — it may contain errors, so check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Read the original at theguardian.com →

More in Health & Medicine

Celltrion ADC Candidates Win FDA Fast Track

All three antibody-drug conjugate (ADC)-based anticancer new drug candidates being developed by Celltrion have been named targets for the Fast Track designation by the U.S.

  • Celltrion secures FDA Fast Track designation for three ADC candidates.
  • CT-P73 targets recurrent and metastatic cervical cancer.
  • Designation aims to expedite development and commercialization.

Novo Nordisk FDA Setback Creates Opportunity for Korean CDMOs

Denmark’s Novo Nordisk, which has led the global pharmaceutical and biotech market on the back of explosive demand for the obesity treatments Wegovy and Ozempic, has run into an unexpected hurdle as…

  • FDA withholds approval for Novo Nordisk facilities due to quality-control violations.
  • Novo Nordisk's Bloomington facility received critical observations, including sterility failures.
  • Korean CDMOs like Celltrion and Samsung Biologics benefit from regulatory challenges.